Lexeo Therapeutics (LXEO) Competitors

$5.12 +0.64 (+14.29%)

Closing price 04:00 PM Eastern

Extended Trading

$5.12 +0.00 (+0.10%)

As of 04:23 PM Eastern

LXEO vs. IMCR, KALV, AMLX, PAHC, and IMTX

Should you buy Lexeo Therapeutics stock or one of its competitors? MarketBeat compares Lexeo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexeo Therapeutics include Immunocore (IMCR), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), Phibro Animal Health (PAHC), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Lexeo Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Immunocore has higher revenue and earnings than Lexeo Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.74	-$35.51M	-$0.55	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.59 beat Lexeo Therapeutics' score of 0.41 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexeo Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Immunocore currently has a consensus target price of $57.75, indicating a potential upside of 95.50%. Lexeo Therapeutics has a consensus target price of $18.88, indicating a potential upside of 268.65%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Immunocore beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

In the previous week, KalVista Pharmaceuticals had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 6 mentions for KalVista Pharmaceuticals and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.41 beat KalVista Pharmaceuticals' score of -0.14 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexeo Therapeutics' return on equity of -47.48% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lexeo Therapeutics has lower revenue, but higher earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,000.98	-$109.52M	-$3.46	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

KalVista Pharmaceuticals currently has a consensus price target of $30.60, indicating a potential upside of 14.14%. Lexeo Therapeutics has a consensus price target of $18.88, indicating a potential upside of 268.65%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Lexeo Therapeutics beats KalVista Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Amylyx Pharmaceuticals presently has a consensus price target of $23.00, indicating a potential upside of 68.99%. Lexeo Therapeutics has a consensus price target of $18.88, indicating a potential upside of 268.65%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexeo Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	17.32	-$144.74M	-$1.50	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Amylyx Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals and Amylyx Pharmaceuticals both had 3 articles in the media. Lexeo Therapeutics' average media sentiment score of 0.41 beat Amylyx Pharmaceuticals' score of -0.12 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexeo Therapeutics' return on equity of -47.48% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Summary

Lexeo Therapeutics beats Amylyx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Phibro Animal Health has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Phibro Animal Health had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Phibro Animal Health and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.41 beat Phibro Animal Health's score of -0.35 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.91	$48.26M	$2.33	14.51
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Phibro Animal Health has a net margin of 6.35% compared to Lexeo Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Phibro Animal Health currently has a consensus target price of $38.80, indicating a potential upside of 14.76%. Lexeo Therapeutics has a consensus target price of $18.88, indicating a potential upside of 268.65%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Phibro Animal Health beats Lexeo Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Immatics?

Lexeo Therapeutics (NASDAQ:LXEO) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Lexeo Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Immatics	-572.35%	-47.36%	-39.35%

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lexeo Therapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Immatics	$54.60M	27.55	-$222.26M	-$1.99	N/A

Lexeo Therapeutics currently has a consensus price target of $18.88, suggesting a potential upside of 268.65%. Immatics has a consensus price target of $19.00, suggesting a potential upside of 69.34%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 2 mentions for Immatics. Lexeo Therapeutics' average media sentiment score of 0.41 beat Immatics' score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexeo Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Immatics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Summary

Lexeo Therapeutics beats Immatics on 11 of the 15 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$402.03M	$3.02B	$6.28B	$12.27B
Dividend Yield	N/A	1.97%	2.80%	5.32%
P/E Ratio	-3.53	17.63	20.74	25.20
Price / Sales	N/A	260.48	532.19	71.01
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	1.74	4.53	9.91	6.97
Net Income	-$99.96M	$74.99M	$3.55B	$335.25M
7 Day Performance	-11.11%	-3.15%	-0.29%	-0.69%
1 Month Performance	-21.59%	-6.57%	-2.52%	-0.95%
1 Year Performance	45.04%	30.21%	30.96%	29.70%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	1.858 of 5 stars	$5.12 +14.3%	$18.88 +268.7%	+36.2%	$402.03M	N/A	N/A	58
IMCR Immunocore	3.2075 of 5 stars	$28.17 -0.7%	$57.75 +105.0%	-6.7%	$1.43B	$400.02M	N/A	320
KALV KalVista Pharmaceuticals	2.455 of 5 stars	$26.78 +0.1%	$30.60 +14.3%	+121.7%	$1.43B	$49.08M	N/A	100	Earnings Report
AMLX Amylyx Pharmaceuticals	2.6822 of 5 stars	$12.59 -2.1%	$23.00 +82.7%	+137.7%	$1.40B	N/A	N/A	200	Gap Up
PAHC Phibro Animal Health	4.4423 of 5 stars	$34.34 +0.5%	$38.80 +13.0%	+40.5%	$1.39B	$1.30B	14.74	2,475

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. IMCR, KALV, AMLX, PAHC, and IMTX

How does Lexeo Therapeutics compare to Immunocore?

Summary

How does Lexeo Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Lexeo Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Lexeo Therapeutics compare to Phibro Animal Health?

Summary

How does Lexeo Therapeutics compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. IMCR, KALV, AMLX, PAHC, and IMTX

How does Lexeo Therapeutics compare to Immunocore?

Which has higher earnings & valuation, IMCR or LXEO?

Which has more volatility and risk, IMCR or LXEO?

Does the media refer more to IMCR or LXEO?

Is IMCR or LXEO more profitable?

Do analysts rate IMCR or LXEO?

Do institutionals & insiders have more ownership in IMCR or LXEO?

Summary

How does Lexeo Therapeutics compare to KalVista Pharmaceuticals?

Does the media refer more to KALV or LXEO?

Is KALV or LXEO more profitable?

Which has more volatility and risk, KALV or LXEO?

Do institutionals and insiders believe in KALV or LXEO?

Which has higher earnings and valuation, KALV or LXEO?

Do analysts prefer KALV or LXEO?

Summary

How does Lexeo Therapeutics compare to Amylyx Pharmaceuticals?

Do analysts rate AMLX or LXEO?

Do insiders and institutionals believe in AMLX or LXEO?

Which has preferable valuation & earnings, AMLX or LXEO?

Which has more risk and volatility, AMLX or LXEO?

Does the media favor AMLX or LXEO?

Is AMLX or LXEO more profitable?

Summary

How does Lexeo Therapeutics compare to Phibro Animal Health?

Which has more risk & volatility, PAHC or LXEO?

Does the media favor PAHC or LXEO?

Which has stronger earnings and valuation, PAHC or LXEO?

Is PAHC or LXEO more profitable?

Do analysts rate PAHC or LXEO?

Do insiders & institutionals believe in PAHC or LXEO?

Summary

How does Lexeo Therapeutics compare to Immatics?

Is LXEO or IMTX more profitable?

Do insiders and institutionals hold more shares of LXEO or IMTX?

Which has preferable valuation and earnings, LXEO or IMTX?

Do analysts recommend LXEO or IMTX?

Does the media prefer LXEO or IMTX?

Which has more risk and volatility, LXEO or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools